Protara Therapeutics, Inc. (TARA)
NASDAQ: TARA · Real-Time Price · USD
3.260
+0.190 (6.19%)
At close: Aug 13, 2025, 4:00 PM
3.280
+0.020 (0.61%)
After-hours: Aug 13, 2025, 7:35 PM EDT

Paramount Global Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202018 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2018 - 2020
Selling, General & Admin
19.8717.4518.6220.7426.422.46
Upgrade
Research & Development
37.4931.724.9916.8121.0911.98
Upgrade
Operating Expenses
57.3549.1543.6137.5547.4934.44
Upgrade
Operating Income
-57.35-49.15-43.61-37.55-47.49-34.44
Upgrade
Interest Expense
------0.03
Upgrade
Interest & Investment Income
5.624.173.191.110.240.5
Upgrade
Other Non Operating Income (Expenses)
0.870.39----
Upgrade
EBT Excluding Unusual Items
-50.86-44.6-40.42-36.44-47.25-33.98
Upgrade
Impairment of Goodwill
----29.52--
Upgrade
Pretax Income
-50.86-44.6-40.42-65.95-47.25-33.98
Upgrade
Net Income
-50.86-44.6-40.42-65.95-47.25-33.98
Upgrade
Net Income to Common
-50.86-44.6-40.42-65.95-47.25-33.98
Upgrade
Shares Outstanding (Basic)
33211111117
Upgrade
Shares Outstanding (Diluted)
33211111117
Upgrade
Shares Change (YoY)
139.68%81.73%0.64%0.24%55.28%180.66%
Upgrade
EPS (Basic)
-1.53-2.17-3.57-5.86-4.21-4.70
Upgrade
EPS (Diluted)
-1.53-2.17-3.57-5.86-4.21-4.70
Upgrade
Free Cash Flow
-44.78-35.87-37.6-26.58-35.1-24.29
Upgrade
Free Cash Flow Per Share
-1.35-1.74-3.32-2.36-3.13-3.36
Upgrade
EBITDA
-57.01-48.82-43.27-37.3-47.37-34.34
Upgrade
D&A For EBITDA
0.350.330.340.250.120.1
Upgrade
EBIT
-57.35-49.15-43.61-37.55-47.49-34.44
Upgrade
Updated May 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q